Blocking ActRIIB and restoring appetite reverses cachexia and improves survival in mice with lung cancer Journal Article


Authors: Queiroz, A. L.; Dantas, E.; Ramsamooj, S.; Murthy, A.; Ahmed, M.; Zunica, E. R. M.; Liang, R. J.; Murphy, J.; Holman, C. D.; Bare, C. J.; Ghahramani, G.; Wu, Z.; Cohen, D. E.; Kirwan, J. P.; Cantley, L. C.; Axelrod, C. L.; Goncalves, M. D.
Article Title: Blocking ActRIIB and restoring appetite reverses cachexia and improves survival in mice with lung cancer
Abstract: Cancer cachexia is a common, debilitating condition with limited therapeutic options. Using an established mouse model of lung cancer, we find that cachexia is characterized by reduced food intake, spontaneous activity, and energy expenditure accompanied by muscle metabolic dysfunction and atrophy. We identify Activin A as a purported driver of cachexia and treat with ActRIIB-Fc, a decoy ligand for TGF-β/activin family members, together with anamorelin (Ana), a ghrelin receptor agonist, to reverse muscle dysfunction and anorexia, respectively. Ana effectively increases food intake but only the combination of drugs increases lean mass, restores spontaneous activity, and improves overall survival. These beneficial effects are limited to female mice and are dependent on ovarian function. In agreement, high expression of Activin A in human lung adenocarcinoma correlates with unfavorable prognosis only in female patients, despite similar expression levels in both sexes. This study suggests that multimodal, sex-specific, therapies are needed to reverse cachexia. © 2022, The Author(s).
Keywords: anorexia; mouse; animal; metabolism; animals; mice; gene expression; carcinoma, non-small-cell lung; lung neoplasms; protein; pathology; food intake; appetite; lung tumor; ligand; rodent; cachexia; muscle; non small cell lung cancer; complication; cancer; humans; human; male; female
Journal Title: Nature Communications
Volume: 13
ISSN: 2041-1723
Publisher: Nature Publishing Group  
Date Published: 2022-08-08
Start Page: 4633
Language: English
DOI: 10.1038/s41467-022-32135-0
PUBMED: 35941104
PROVIDER: scopus
PMCID: PMC9360437
DOI/URL:
Notes: Article -- Export Date: 1 September 2022 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Charles Joseph Murphy
    5 Murphy